Bruce Mitlak
Overview
Explore the profile of Bruce Mitlak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
446
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Dhaliwal R, Hans D, Hattersley G, Mitlak B, Fitzpatrick L, Wang Y, et al.
JBMR Plus
. 2021 Feb;
5(2):e10414.
PMID: 33615100
[This corrects the article DOI: 10.1002/jbm4.10346.].
12.
Miller P, Bilezikian J, Fitzpatrick L, Mitlak B, McCloskey E, Cosman F, et al.
Curr Med Res Opin
. 2020 Sep;
36(11):1861-1872.
PMID: 32969719
Objective: Fractures due to osteoporosis represent a serious burden on patients and healthcare systems. The objective of this review is to provide an overview of the anabolic agent abaloparatide (ABL)...
13.
Eastell R, Black D, Lui L, Chines A, Marin F, Khosla S, et al.
J Bone Miner Res
. 2020 Sep;
36(2):236-243.
PMID: 32916023
Few analyses of antiresorptive (AR) treatment trials relate short-term changes in bone turnover markers (BTMs) to subsequent fracture reduction seeking to estimate the proportion of treatment effect explained (PTE) by...
14.
Black D, Bauer D, Vittinghoff E, Lui L, Grauer A, Marin F, et al.
Lancet Diabetes Endocrinol
. 2020 Jul;
8(8):672-682.
PMID: 32707115
Background: The validation of bone mineral density (BMD) as a surrogate outcome for fracture would allow the size of future randomised controlled osteoporosis registration trials to be reduced. We aimed...
15.
Greenspan S, Fitzpatrick L, Mitlak B, Wang Y, Harvey N, Deal C, et al.
Menopause
. 2020 Jul;
27(10):1137-1142.
PMID: 32665529
Objective: Fracture risk increases with age, but few studies focus on persons ≥80 years. In the ACTIVE trial, treatment with abaloparatide for 18 months reduced osteoporotic fracture risk and increased...
16.
Cosman F, Peterson L, Towler D, Mitlak B, Wang Y, Cummings S
J Clin Endocrinol Metab
. 2020 Jul;
105(11).
PMID: 32658264
Context: Abaloparatide is a US Food and Drug Administration-approved parathyroid hormone-related peptide analog for treatment of osteoporosis in postmenopausal women at high risk of fracture. Objectives: We assessed the cardiovascular...
17.
Arlt H, Mullarkey T, Hu D, Baron R, Ominsky M, Mitlak B, et al.
Bone Rep
. 2020 Jul;
13:100291.
PMID: 32637467
Intermittent administration of PTH type 1 receptor (PTH1R) agonists increases bone remodeling, with greater stimulation of bone formation relative to bone resorption causing net gains in bone mass. This pharmacodynamic...
18.
Leder B, Mitlak B, Hu M, Hattersley G, Bockman R
J Clin Endocrinol Metab
. 2020 Jun;
105(8).
PMID: 32516411
No abstract available.
19.
Dhaliwal R, Hans D, Hattersley G, Mitlak B, Fitzpatrick L, Wang Y, et al.
JBMR Plus
. 2020 Apr;
4(4):e10346.
PMID: 32258965
Type 2 diabetes mellitus (T2DM) increases fracture risk despite normal or increased BMD. Abaloparatide reduces fracture risk in patients with postmenopausal osteoporosis (PMO); however, its efficacy in women with T2DM...
20.
Leder B, Mitlak B, Hu M, Hattersley G, Bockman R
J Clin Endocrinol Metab
. 2019 Nov;
105(3).
PMID: 31674644
Context: The ACTIVE study demonstrated the antifracture efficacy of abaloparatide in postmenopausal women with osteoporosis. ACTIVExtend demonstrated sustained fracture risk reduction with alendronate in abaloparatide-treated participants from ACTIVE. A direct...